Skip to main content

Table 3 Cerebrospinal fluid biomarker findings

From: A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease

Change from baseline at week 104 Placebo Gantenerumab 105 mg Gantenerumab 225 mg
Change (%), median (Q1, Q3) Change (%), median (Q1, Q3) p Value vs placebo Change (%), median (Q1, Q3) p Value vs placebo
42, pg/ml n = 72
−0.85%
(−15.31, 21.03)
n = 71
−1.06%
(−19.33, 25.88)
0.98 n = 66
7.55%
(−13.96, 35.09)
0.09
t-tau, pg/ml n = 72
2.04%
(−4.56, 8.72)
n = 71
−1.08%
(−7.65, 5.86)
0.05 n = 66
−2.91%
(−8.54, 3.40)
0.02
p-tau, pg/ml n = 72
0.08%
(−3.91, 6.49)
n = 71
−5.61%
(−11.07, 0.97)
≤ 0.001 n = 66
−7.15%
(−14.48, −2.41)
≤ 0.001
Neurogranin, pg/ml n = 65
−3.24%
(−20.64, 12.27)
n = 66
−4.58%
(−19.89, 10.13)
0.79 n = 63
−11.76%
(−23.69, 6.48)
0.18
  1. Abbreviations: Aβ Amyloid-beta, p-tau Phosphorylated tau, t-tau Total tau